title: Tapentadol prolonged release for severe chronic cancer-related pain: effectiveness, tolerability, and influence on quality of life of the patients.
abstract: BACKGROUND
  Clinical trials have shown the efficacy and good tolerability of tapentadol prolonged release (PR) for severe chronic pain of different etiologies. This study investigated the influence of tapentadol PR on pain control and quality of life of patients with severe chronic cancer-related pain in routine clinical practice in Germany.
  
  
  METHODS
  During a 3-month observation period, 45 physicians (mainly palliative care specialists) documented dosage and tolerability of tapentadol PR, previous and concomitant analgesic treatment, pain intensity, pain-related restrictions of daily activities and quality of life, and general state of health of 123 patients with chronic cancer-related pain in the context of a prospective noninterventional study.
  
  
  RESULTS
  All patients (mean age 63.9±13.2 years, 93.5% in constant pain) had received analgesic long-term treatment (42.3% strong opioids) prior to the start of tapentadol PR treatment. During the observation period, tapentadol PR significantly reduced the average pain intensity by 2.4 points (from a mean 6.1±1.7 to 3.7±2.0, P<0.001); half of the patients (52%) achieved a pain score ≤3 at the end of observation. At the same time, mental and emotional well-being, pain-related impairments of daily activities, sleep quality, and quality of life improved, while the overall intake of analgesic concomitant medication could be reduced. Improvements in general state of health were significant (P<0.001). Overall, tapentadol PR was well tolerated.
  
  
  CONCLUSIONS
  Good pain control with tapentadol PR was accompanied by markedly reduced pain-related mental and physical burden and quality of life improved. Overall, the general state of health of these patients with chronic cancer-related pain improved significantly despite the underlying illness.
authors.affiliation: Neurology and Specialist Pain Therapy, Specialist Center Düsseldorf, Düsseldorf, Germany.
authors.forename: Artur
authors.initials: A
authors.lastname: Schikowski
authors.affiliation: Grünenthal GmbH, Aachen, Germany.
authors.forename: Doris
authors.initials: D
authors.lastname: Krings
authors.affiliation: Grünenthal GmbH, Aachen, Germany.
authors.forename: Karla
authors.initials: K
authors.lastname: Schwenke
keywords: chronic cancer-related pain; daily clinical practice; pain treatment; quality of life; tapentadol PR